Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

863 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M, Del Mastro L, Melioli G, Balleari E, Garrone O, Pasquetti W, Bason C, Ghio R, Bruzzi P, Rosso R. Venturini M, et al. Among authors: rosso r. Cancer. 1994 Oct 15;74(8):2300-6. doi: 10.1002/1097-0142(19941015)74:8<2300::aid-cncr2820740814>3.0.co;2-k. Cancer. 1994. PMID: 7522948
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R, et al. Ardizzoni A, et al. Among authors: rosso r. Eur J Cancer. 1993;29A(5):687-92. doi: 10.1016/s0959-8049(05)80347-8. Eur J Cancer. 1993. PMID: 8385970
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR. Venturini M, et al. Among authors: rosso r. J Clin Oncol. 1996 Mar;14(3):764-73. doi: 10.1200/JCO.1996.14.3.764. J Clin Oncol. 1996. PMID: 8622022 Clinical Trial.
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R. Venturini M, et al. Among authors: rosso r. Cancer Chemother Pharmacol. 1996;38(6):487-94. doi: 10.1007/s002800050516. Cancer Chemother Pharmacol. 1996. PMID: 8823488
Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
Ardizzoni A, Pennucci MC, Danova M, Viscoli C, Mariani GL, Giorgi G, Venturini M, Mereu C, Scolaro T, Rosso R. Ardizzoni A, et al. Among authors: rosso r. Br J Cancer. 1996 Oct;74(7):1141-7. doi: 10.1038/bjc.1996.504. Br J Cancer. 1996. PMID: 8855989 Free PMC article. Clinical Trial.
863 results